Normal view MARC view ISBD view

Infliximab : (Record no. 42264)

MARC details
000 -LEADER
fixed length control field	05736cam a2200757 i 4500
001 - CONTROL NUMBER
control field	on1162002557
003 - CONTROL NUMBER IDENTIFIER
control field	OCoLC
005 - DATE AND TIME OF LATEST TRANSACTION
control field	20201015090345.0
006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS
fixed length control field	m o d
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION
fixed length control field	cr \|\|\|\|\|\|\|\|\|\|\|
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field	120802s2012 nyu ob 001 0 eng
010 ## - LIBRARY OF CONGRESS CONTROL NUMBER
LC control number	2020677201
040 ## - CATALOGING SOURCE
Original cataloging agency	DLC
Language of cataloging	eng
Description conventions	rda
Transcribing agency	DLC
Modifying agency	VLY
--	OCLCO
--	AZK
--	YDXCP
--	N$T
--	E7B
--	OCLCF
--	NLGGC
--	EBLCP
--	LOA
--	MERUC
--	AGLDB
--	ICA
--	MOR
--	PIFAG
--	ZCU
--	U3W
--	D6H
--	STF
--	WRM
--	VTS
--	NRAMU
--	ICG
--	VT2
--	WYU
--	DKC
--	AU@
--	M8D
--	K6U
--	UKCRE
019 ## -
--	828140625
--	923654270
--	961573436
--	962684398
--	966182436
--	988436558
--	992028910
--	1037927216
--	1038665338
--	1045509625
--	1055383791
--	1066451555
--	1081210814
--	1153513512
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number	9781619423459
Qualifying information	(ebook)
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number	1619423456
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
Canceled/invalid ISBN	9781619423435
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
Canceled/invalid ISBN	161942343X
Qualifying information	(hbk.)
029 1# - OTHER SYSTEM CONTROL NUMBER (OCLC)
OCLC library identifier	AU@
System control number	000059385624
029 1# - OTHER SYSTEM CONTROL NUMBER (OCLC)
OCLC library identifier	DEBBG
System control number	BV041049667
029 1# - OTHER SYSTEM CONTROL NUMBER (OCLC)
OCLC library identifier	DEBBG
System control number	BV043961304
029 1# - OTHER SYSTEM CONTROL NUMBER (OCLC)
OCLC library identifier	DEBBG
System control number	BV044087302
029 1# - OTHER SYSTEM CONTROL NUMBER (OCLC)
OCLC library identifier	DEBSZ
System control number	481298959
029 1# - OTHER SYSTEM CONTROL NUMBER (OCLC)
OCLC library identifier	NZ1
System control number	15025247
035 ## - SYSTEM CONTROL NUMBER
System control number	(OCoLC)1162002557
Canceled/invalid control number	(OCoLC)828140625
--	(OCoLC)923654270
--	(OCoLC)961573436
--	(OCoLC)962684398
--	(OCoLC)966182436
--	(OCoLC)988436558
--	(OCoLC)992028910
--	(OCoLC)1037927216
--	(OCoLC)1038665338
--	(OCoLC)1045509625
--	(OCoLC)1055383791
--	(OCoLC)1066451555
--	(OCoLC)1081210814
--	(OCoLC)1153513512
050 00 - LIBRARY OF CONGRESS CALL NUMBER
Classification number	RM405.5
060 #4 - NATIONAL LIBRARY OF MEDICINE CALL NUMBER
Classification number	WD 305
072 #7 - SUBJECT CATEGORY CODE
Subject category code	MED
Subject category code subdivision	044000
Source	bisacsh
082 00 - DEWEY DECIMAL CLASSIFICATION NUMBER
Classification number	615.7/94
Edition number	23
049 ## - LOCAL HOLDINGS (OCLC)
Holding library	MAIN
245 00 - TITLE STATEMENT
Title	Infliximab :
Remainder of title	pharmacology, uses and limitations /
Statement of responsibility, etc.	Antonio D. Medrano Acevedo and Montserrat Fajardo Gaitan, editors.
264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE
Place of production, publication, distribution, manufacture	New York :
Name of producer, publisher, distributor, manufacturer	Nova Science Publishers, Incorporated,
Date of production, publication, distribution, manufacture, or copyright notice	[2012]
300 ## - PHYSICAL DESCRIPTION
Extent	1 online resource.
336 ## - CONTENT TYPE
Content type term	text
Content type code	txt
Source	rdacontent
337 ## - MEDIA TYPE
Media type term	computer
Media type code	c
Source	rdamedia
338 ## - CARRIER TYPE
Carrier type term	online resource
Carrier type code	cr
Source	rdacarrier
347 ## - DIGITAL FILE CHARACTERISTICS
File type	data file
Source	rda
380 ## - FORM OF WORK
Form of work	Bibliography
490 1# - SERIES STATEMENT
Series statement	Immunology and immune system disorders
504 ## - BIBLIOGRAPHY, ETC. NOTE
Bibliography, etc. note	Includes bibliographical references and index.
588 ## - SOURCE OF DESCRIPTION NOTE
Source of description note	Description based on print version record.
505 0# - FORMATTED CONTENTS NOTE
Formatted contents note	""INFLIXIMAB PHARMACOLOGY, USES AND LIMITATIONS ""; ""INFLIXIMAB PHARMACOLOGY, USES AND LIMITATIONS ""; ""Contents ""; ""Preface ""; ""The Risk of Infection in Patients Treated with Infliximab ""; ""Abstract ""; ""1. Definition and Functions of Tumour Necrosis Factor ""; ""2. Anti-TNF Mechanism of Action: Infliximab ""; ""3. Risk of Infections in the Use of Infliximab: Evidence""; ""4. Risk of Infection from the Use of Anti-TNF (Inflximab): Mechanisms Involved""; ""5. Other Risk Factors for Infection in Patients Treated with Infliximab ""; ""6. Infections ""; ""Bacterial Infections""
505 8# - FORMATTED CONTENTS NOTE
Formatted contents note	""Listeria """"Tuberculosis ""; ""Virus ""; ""Fungal Infections ""; ""Histoplasmosis ""; ""Coccidioidomycosis ""; ""Cryptococcosis ""; ""Aspergillosis ""; ""Candidiasis""; ""Pneumocystosis ""; ""7. Special Situations""; ""Perisurgical Infections ""; ""Hepatitis B Virus Infection ""; ""Hepatitis C Virus Infection ""; ""HIV Infection ""; ""Vaccines ""; ""Conclusions ""; ""References ""; ""Infliximab in Inflammatory Bowel Disease ""; ""Abstract ""; ""Pharmacology""; ""Uses ""; ""Inflammatory Crohn�a�?s Disease ""; ""Fistulizing Crohn�a�?s Disease ""; ""Ulcerative Colitis""; ""Mucosal Healing ""
505 8# - FORMATTED CONTENTS NOTE
Formatted contents note	""Pouchitis""""Extraintestinal Manifestations ""; ""Limitations ""; ""Predictors of Response to Infliximab ""; ""Infections ""; ""Malignancies and Lymphoma ""; ""Cutaneous, Neurological and Liver Manifestations ""; ""Congestive Heart Failure ""; ""Pregnancy ""; ""References ""; ""Infliximab: Up-to-Date on Indications and Warnings ""; ""Abstract ""; ""1. Introduction""; ""2. Pharmacology""; ""2.1. Structure and Mechanisms of Action""; ""2.2. Absorption ""; ""2.3. Distribution ""; ""2.4. Metabolism and Excretion ""; ""2.5. Dosage and Administration ""; ""2.6. Pharmacogenomics""
505 8# - FORMATTED CONTENTS NOTE
Formatted contents note	""D) Chronic Eczema """"E) Hidradenitis Susppurativa (HS) ""; ""3.3. Other Verified Uses ""; ""a) SAPHO Syndrome ""; ""b) Kawasaki Disease ""; ""c) Pulmonary Fibrosis ""; ""d) Cap Polyposis ""; ""e) Postresuscitation Myocardial Dysfunction ""; ""f) B-Chronic Lymphocytic Leukemia ""; ""g) Diabetic Macular Edema ""; ""4. Warnings and Limitations""; ""4.1. Serious Infections ""; ""4.2. Malignancies ""; ""4.3. Hepatitis B virus Reactivation ""; ""4.4. Hepatotoxicity ""; ""4.5. Patients with Heart Failure ""; ""4.6. Hematological and Vascular Events ""; ""4.7. Hypersensitivity ""
546 ## - LANGUAGE NOTE
Language note	English.
590 ## - LOCAL NOTE (RLIN)
Local note	eBooks on EBSCOhost
Provenance (VM) [OBSOLETE]	EBSCO eBook Subscription Academic Collection - Worldwide
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element	Infliximab.
Authority record control number or standard number	http://id.loc.gov/authorities/subjects/sh2002010978
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element	Infliximab
General subdivision	Therapeutic use.
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element	Anti-inflammatory agents.
Authority record control number or standard number	http://id.loc.gov/authorities/subjects/sh85005615
650 #2 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element	Autoimmune Diseases
General subdivision	drug therapy.
650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element	MEDICAL
General subdivision	Immunology.
Source of heading or term	bisacsh
650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element	Autoimmune diseases
General subdivision	Chemotherapy.
Source of heading or term	fast
Authority record control number or standard number	(OCoLC)fst00822665
650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element	Infliximab.
Source of heading or term	fast
Authority record control number or standard number	(OCoLC)fst00972480
655 #4 - INDEX TERM--GENRE/FORM
Genre/form data or focus term	Electronic books.
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name	Medrano Acevedo, Antonio D.
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name	Fajardo Gaitan, Montserrat.
776 08 - ADDITIONAL PHYSICAL FORM ENTRY
Relationship information	Print version:
Title	Infliximab
Place, publisher, and date of publication	[Hauppauge] New York : Nova Science Publishers, Inc., [2012]
International Standard Book Number	9781619423435
Record control number	(DLC) 2012418415
830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE
Uniform title	Immunology and immune system disorders.
Authority record control number or standard number	http://id.loc.gov/authorities/names/n2010183470
856 40 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier	https://libproxy.firstcity.edu.my:8443/login?url=http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=540914
938 ## -
--	ProQuest Ebook Central
--	EBLB
--	EBL3017947
938 ## -
--	ebrary
--	EBRY
--	ebr10654918
938 ## -
--	EBSCOhost
--	EBSC
--	540914
938 ## -
--	YBP Library Services
--	YANK
--	7252252
994 ## -
--	92
--	MYFCU

No items available.